Memantine/donepezil

From WikiProjectMed
Jump to navigation Jump to search

Memantine/donepezil
Combination of
MemantineNMDA receptor antagonist
DonepezilAcetylcholinesterase inhibitor
Clinical data
Trade namesNamzaric
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Memantine/donepezil, sold under the brand name Namzaric, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type.[1] It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor.[1] It is taken by mouth.[1]

Memantine/donepezil was approved for medical use in the United States in 2014.[2]

References

  1. ^ a b c d "Namzaric- memantine hydrochloride and donepezil hydrochloride capsule; Namzaric- memantine hydrochloride and donepezil hydrochloride kit". DailyMed. 22 January 2019. Archived from the original on 20 January 2022. Retrieved 22 December 2023.
  2. ^ "Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules". U.S. Food and Drug Administration (FDA). 13 May 2015. Archived from the original on 22 December 2023. Retrieved 22 December 2023.

Further reading


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/Memantine/donepezil"